# Christopher Lübker

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/christopher-lubker/

## Facts

| Field | Value |
| --- | --- |
| Citations | 246 |
| Field | Diabetes Treatment and Management |
| h-index | 6 |
| i10-index | 6 |
| Last Known Institution | Novo Nordisk (Denmark) |
| OpenAlex ID | https://openalex.org/A5059266337 |
| ORCID iD | 0000-0003-3220-801X |
| Works | 21 |

## Researcher papers

- [Educational inequalities in longevity among OECD countries around 2016](https://scholariq.org/papers/educational-inequalities-in-longevity-among-oecd-countries-around-2016/)
- [Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom](https://scholariq.org/papers/once-weekly-subcutaneous-semaglutide-2-4-mg-injection-is-cost-effective-for/)
- [Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes](https://scholariq.org/papers/cost-effectiveness-of-semaglutide-in-people-with-obesity-and-cardiovascular/)
- [Changes in longevity inequality by education among OECD countries before the COVID-19 pandemic](https://scholariq.org/papers/changes-in-longevity-inequality-by-education-among-oecd-countries-before-the/)
- [The association between body mass index and health‐related quality of life in the 2017 and 2018 health survey of England data: A cross‐sectional observational analysis](https://scholariq.org/papers/the-association-between-body-mass-index-and-health-related-quality-of-life-in/)
- [Educational inequalities in deaths of despair in 14 OECD countries: a cross-sectional observational study](https://scholariq.org/papers/educational-inequalities-in-deaths-of-despair-in-14-oecd-countries-a-cross/)
- [The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials](https://scholariq.org/papers/the-improved-health-utility-of-once-weekly-subcutaneous-semaglutide-2-4-mg/)
- [The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes](https://scholariq.org/papers/the-composite-number-needed-to-treat-for-semaglutide-in-populations-with/)
- [EE497 The Cost-Effectiveness of Semaglutide 2.4MG in Patients With Overweight/Obesity and Cardiovascular Disease From the Select Trial](https://scholariq.org/papers/ee497-the-cost-effectiveness-of-semaglutide-2-4mg-in-patients-with-overweight/)
- [Impact of Body Mass Index and Comorbidities on Health-Related Quality of Life and Work Productivity in People With Overweight or Obesity: A Survey-Based Study in the United Kingdom](https://scholariq.org/papers/impact-of-body-mass-index-and-comorbidities-on-health-related-quality-of-life/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Health disparities and outcomes](https://scholariq.org/topics/health-disparities-and-outcomes/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Obesity, Physical Activity, Diet](https://scholariq.org/topics/obesity-physical-activity-diet/)

## Researcher university

- [Novo Nordisk (Denmark)](https://scholariq.org/institutions/novo-nordisk-denmark/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.